TRAILRUNNER-ALZ 2: Remternetug in Alzheimer’s disease
Research type
Research Study
Full title
Assessment of safety and efficacy of subcutaneous remternetug in early symptomatic Alzheimer’s disease.
IRAS ID
1004300
Contact name
Maria Del Mar Moreno
Contact email
Sponsor organisation
Eli Lilly and Company Ltd
Research summary
Dementia is a group of related symptoms associated with an ongoing decline of brain functioning. Alzheimer's disease (AD) is the most common type of dementia in the UK. The exact cause of AD is not yet fully understood, although a number of factors are thought to increase your risk of developing the condition including increasing age and family history. AD is a progressive condition, where symptoms developgradually and eventually become more severe. It affects multiple brain functions.
AD is thought to be caused by the abnormal build-up of proteins in and around brain cells. One of the proteins involved is called amyloid, deposits of which form plaques around brain cells. It is suggested that interventions that clear these plaques may slow the progression of AD. Remternetug is an antibody that targets and removes deposited amyloid plaques.
The study TRAILRUNNER-ALZ 2 will assess whether treatment with remternetug can slow the progression of the disease in patients with early symptomatic AD. Study participants will receive either remternetug or placebo, subcutaneous injection (SC) once weekly. All participants will have the opportunity to receive remternetug.
Patient participation is expected to last up to 155 weeks. The patient will actually receive treatment for approximately 36 weeks (36 doses). Approximately 1300 participants will be enrolled in the study globally, including approximately 102 participants from the UK.
REC name
London - Hampstead Research Ethics Committee
REC reference
23/LO/0125
Date of REC Opinion
26 Apr 2023
REC opinion
Further Information Favourable Opinion